Wednesday, April 22, 2026
29.4 C
Bengaluru

An Infectious Disease Specialist Speaks to Pharma on How it Needs to Change its Approach

linkedin.com/in/dr-mandar-kubal-3721352

Key Point from the Q &A with Dr. Mandar Kubal, Mumbai

Telemedicine has become a very useful tool for clinicians to manage their patients.

Given the ever changing contours of Covid19 treatment, doctors have to check daily for online resources.

It would be wonderful if pharma can provide every specialty the latest developments in treating Covid19 with pre existing conditions instead of sending their unvaccinated field force to give brand reminders.

Pharma should seek frontline worker status for Medical Reps and Field Managers as they are critical to maintain the drug supply chain.

Treat the Field Force as an asset and protect them, instead of pushing them onto the field without vaccination.

And many more insights from a clinician at the frontlines of treating Covid19 patients.

An Infectious Disease Specialist Speaks to Pharma on How it Needs to Change its Approach @YouTube

………………………………………………………………………………………………………………………….

Digital Excellence Pharma Academy (DEPA) begins a new series of conversations with doctors to Indian Pharma and insight into their challenges and how pharma needs to change its current approach to interactions with doctors

Great Opportunity for Pharma People to Listen to What Doctors have to Say https://youtu.be/wqCK574qb-g
Conversation with Dr. Deepak Krishnamurthy on Expectations of Doctors from Pharma https://youtu.be/7VVzhMlY2Uw

You can also listen to what pharma leaders from across the globe have to say about various aspects of pharma’s challenges and solutions on MedicinMan YouTube Channel – https://www.youtube.com/channel/UCEj-fkwCUJGVW0-FmipRP3A

Hot this week

Will the GLP Battle Now Shift from Injectable to Oral?

In India’s million-strong retail pharmacy universe, oral weight-loss pills...

The Semaglutide Paradox: Anatomy of a High-Stakes Commodity Trap

The Semaglutide Shift: From Blockbuster to Commodity Why the $50...

Cytotoxics to Cell Therapy: A 40-Year Review of Indian Oncology Strategy

In 1989, oncology in India was not a business...

Ritesh Desai has joined Standard Chartered India as Executive Director

Ritesh Desai has joined Standard Chartered India as Executive...

The Healthium Odyssey: From Sutures to Scalpel-Sharp Innovation

The story of Healthium is not just one of...

Topics

Will the GLP Battle Now Shift from Injectable to Oral?

In India’s million-strong retail pharmacy universe, oral weight-loss pills...

The Semaglutide Paradox: Anatomy of a High-Stakes Commodity Trap

The Semaglutide Shift: From Blockbuster to Commodity Why the $50...

Ritesh Desai has joined Standard Chartered India as Executive Director

Ritesh Desai has joined Standard Chartered India as Executive...

A Tale of Two Companies – Sun Pharma’s Odyssey and Organon’s Second Act

Sun Pharma’s Odyssey and Organon’s Second Act – And...

The Semaglutide Gold Rush: Miracle Cure or Market Mirage?

The Indian Pharmaceutical Market (IPM) has entered a definitive...
spot_img

Related Articles

spot_imgspot_img